Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals — Q3 2025 Earnings Presentation
16 slides from Day One Biopharmaceuticals's earnings presentation, Nov 4, 2025
Slide 1: Third Quarter 2025 Financial Results & Corporate Progress
NOVEMBER 2025 Third Quarter 2025 Financial Results & Corporate Progress
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and unc
Slide 3: Agenda & Day One Participants
Agenda & Day One Participants Opening Remarks Jeremy Bender (Chief Executive Officer) OJEMDATM Launch Performance Lauren Merendino (Chief Commercial Officer) Financial Performance Charles York (Chief Operating & Chief Financial Officer) Q&A Session All, joined by: Mike Vasconcelles (Head of R&D)
Slide 4: Opening Remarks
Opening Remarks Jeremy Bender Chief Executive Officer
Slide 5: Third Quarter 2025 Highlights – Growth Across All Dimensions of our Core Business
Third Quarter 2025 Highlights – Growth Across All Dimensions of our Core Business EMA: European Medicines Agency 1 Regulatory submission process executed by Ipsen 2 Represents cash, cash equivalents and short-term investments as of September 30, 2025. Financial Position Pipeline Progress $38.5M in n
Slide 6: OJEMDA Launch Performance
OJEMDA Launch Performance Lauren Merendino Chief Commercial Officer
Slide 7: Delivering Double-Digit Q3 2025 Growth Across Core Metrics
Delivering Double-Digit Q3 2025 Growth Across Core Metrics 1 Prescriptions are approximations based on data available as of September 30, 2025. Quarterly growth in net product revenue, prescriptions and new patient starts versus Q2 2025. 15% Growth in Net Product Revenue 18% $38.5M in Q3 2025 19% Gr
Slide 8: Commercial Execution Driving Strong Top-Line Growth and Performance
1 2024 net revenue included approximately $3.0M of revenue associated with Ex-U.S. sales which has been removed for the purposes of calculating compounded annual revenue growth rate. 2 Compounded annual growth represents the comparison of 2024 to Q3 2025 YTD U.S. net product revenue. Commercial Exec
Slide 9: Accelerating Uptake Driving TRx Growth and Demonstrating Durable Demand
19% growth in new patient starts driven by 2-year follow up data3 Prescription Highlights Gaining share in the 2L setting as prescriber confidence grows High percentage of on-label patients staying on therapy month-to-month ~90% of on-label patients receiving approval on first request Accelerating U
Slide 10: Positive Physician Experience Continues to Build Across Treatment Settings
Positive Physician Experience Continues to Build Across Treatment Settings 1 Day One Biopharmaceuticals market research, self-reported data fielded September 2025 versus October 2024. Strong Persistency 2L Adoption Increasing 20 months median duration of treatment for EAP patients 75% of EAP patient
Slide 11: Prescriber Confidence Driving Repeat Use with Significant Opportunity Remaining
1 Sequential growth refers to Q3 2025 versus Q2 2025. >60% of prescribing accounts have treated multiple patients with OJEMDA 28% sequential growth in number of accounts with 4 or more patients1 >80% Priority 1 accounts have initiated 4 or more patients Launch Dec 2024 Sept 2025 1 Patient 2-3 Patien
Slide 12: Focused Execution and Meaningful Progress Driving Continued Adoption
Focused Execution and Meaningful Progress Driving Continued Adoption and Treatment Durability through 2025 On label patients only. Raising 2025 guidance to $145 - $150 million net product revenue OPTIMIZE PERSISTENCE Support physicians and patients to optimize their experience on OJEMDA including ef
Slide 13: Strengthening the OJEMDA Story Through Target Product Profile and Data Generation
We Continue to Strengthen the OJEMDA Story Through Enhancing the Target Product Profile and Data Generation FIREFLY-1 3-Year Data Highlighting clinical stability following treatment with OJEMDA and opportunity for retreatment Potential to further expand physician confidence and adoption while reinfo
Slide 14: Financial Performance
Financial Performance Charles York Chief Operating Officer & Chief Financial Officer
Slide 15: Third Quarter 2025 Financial Results
All financial information as of 9/30/25 is unaudited. 1 Includes stock-based compensation expense of $3.0 million and $10.8 million for the three and nine months ended 9/30/25, and $3.8 million and $13.2 million for the three and nine months ended 9/30/24. 2 Includes stock-based compensation expense
Slide 16: Thank You
Thank You
Day One Biopharmaceuticals — Q3 2025 Earnings Presentation on 6ix